Log in

Relevant bibliographies by topics / Asbestos pleural disease / Journal articles

To see the other types of publications on this topic, follow the link: Asbestos pleural disease.

Journal articles on the topic 'Asbestos pleural disease'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Asbestos pleural disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Perić, Irena, Katarina Novak, Igor Barišić, Kornelija Miše, Maja Vučković, Stipan Janković, and Jadranka Tocilj. "Interobserver Variations in Diagnosing Asbestosis According to the ILO Classification." Archives of Industrial Hygiene and Toxicology 60, no. 2 (June 1, 2009): 191–95. http://dx.doi.org/10.2478/10004-1254-60-2009-1904.

Full text

Abstract:

Interobserver Variations in Diagnosing Asbestosis According to the ILO ClassificationInhalation of asbestos fibres leads to asbestosis of the pleura and the lung, with possible progression to lung cancer and malignant pleural or peritoneal mesothelioma. Asbestosis remains difficult to diagnose, especially in its early stages. The most important role in its diagnosis is that of chest radiographs. The aim of this cross-sectional study was to address interobserver variations in interpreting chest radiographs in asbestos workers, which remain to be an issue, despite improvements in the International Labour Office (ILO) classification system. In our ten-year study, we investigated 318 workers occupationally exposed to asbestos, and in 210 workers with diagnosed asbestos-related changes we compared interpretations of chest radiographs according to ILO by two independent radiologists. The apparent degree of interobserver variation in classifying lung fibrosis was 26.66% for the diameter of changes and 42.2% for the profusion of the changes. In cases with diffuse pleural thickening, the interobserver variation using ILO procedures was 34.93%. This investigation raises the issue of standardisation and objectivity of interpretation of asbestosis according to the ILO classification system. This study has revealed a significant disagreement in the estimated degree of pleural and parenchymal asbestos pulmonary disease. This is why we believe high-resolution computed tomography (HRCT) should also be used as a part of international classification.

APA, Harvard, Vancouver, ISO, and other styles

2

Franko, Alenka, Katja Goricar, Metoda Dodic Fikfak, Viljem Kovac, and Vita Dolzan. "The role of polymorphisms in glutathione-related genes in asbestos-related diseases." Radiology and Oncology 55, no. 2 (January 26, 2021): 179–86. http://dx.doi.org/10.2478/raon-2021-0002.

Full text

Abstract:

Abstract Background The study investigated the influence of GCLC, GCLM, GSTM1, GSTT1 and GSTP1 polymorphisms, as well as the influence of interactions between polymorphism and interactions between polymorphisms and asbestos exposure, on the risk of developing pleural plaques, asbestosis and malignant mesothelioma (MM). Subjects and methods The cross sectional study included 940 asbestos-exposed subjects, among them 390 subjects with pleural plaques, 147 subjects with asbestosis, 225 subjects with MM and 178 subjects with no asbestos-related disease. GCLC rs17883901, GCLM rs41303970, GSTM1 null, GSTT1 null, GSTP1 rs1695 and GSTP1 rs1138272 genotypes were determined using PCR based methods. In statistical analysis, logistic regression was used. Results GSTT1 null genotype was associated with the decreased risk for pleural plaques (OR = 0.63; 95% CI = 0.40–0.98; p = 0.026) and asbestosis (OR = 0.51; 95% CI = 0.28–0.93; p = 0.028), but not for MM. A positive association was found between GSTP1 rs1695 AG + GG vs. AA genotypes for MM when compared to pleural plaques (OR = 1.39; 95% CI = 1.00–1.94; p = 0.049). The interactions between different polymorphisms showed no significant influence on the risk of investigated asbestos-related diseases. The interaction between GSTT1 null polymorphism and asbestos exposure decreased the MM risk (OR = 0.17; 95% CI = 0.03–0.85; p = 0.031). Conclusions Our findings suggest that GSTT1 null genotype may be associated with a decreased risk for pleural plaques and asbestosis, may modify the association between asbestos exposure and MM and may consequently act protectively on MM risk. This study also revealed a protective effect of the interaction between GSTP1 rs1695 polymorphism and asbestos exposure on MM risk.

APA, Harvard, Vancouver, ISO, and other styles

3

Roggli, Victor L. "The Contributions Of Analytical Electron Microscopy to the Detection and Quantification of Asbestos in Human Lung Samples." Proceedings, annual meeting, Electron Microscopy Society of America 48, no. 2 (August 12, 1990): 340–41. http://dx.doi.org/10.1017/s0424820100135307.

Full text

Abstract:

Analytical electron microscopy has contributed a great deal to our understanding of asbestosrelated diseases. Exposure to the various forms of asbestos, which include the serpentine form known as chrysotile asbestos, and the amphibole forms referred to as amosite, crocidolite, tremolite, anthophyllite, and actinolite asbestos, has been associated with the development of a number of diseases in man. These include asbestosis (scarring of the lung parenchyma), pleural plaques (scarring of the pleura), malignant mesothelioma of the pleura and peritoneum, and carcinoma of the lung, especially among those who also smoke cigarettes.Analysis of the mineral fiber content of the lung in patients with these various diseases has provided a powerful investigative tool to researchers interested in the relationship between fiber burdens and disease. Such studies have shown that when sufficiently sensitive digestion concentration techniques are employed, some asbestos can be found in lung tissue from virtually every adult in the general population.

APA, Harvard, Vancouver, ISO, and other styles

4

Nishimura, Stephen L., and V. Courtney Broaddus. "ASBESTOS-INDUCED PLEURAL DISEASE." Clinics in Chest Medicine 19, no. 2 (June 1998): 311–29. http://dx.doi.org/10.1016/s0272-5231(05)70079-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Hillerdal, Gunnar. "Asbestos-Related Pleural Disease." Seminars in Respiratory and Critical Care Medicine 9, no. 01 (July 1987): 65–74. http://dx.doi.org/10.1055/s-2007-1012690.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Smith, Dorsett D. "Asbestos-Related Pleural Disease." Clinical Pulmonary Medicine 1, no. 5 (September 1994): 289–300. http://dx.doi.org/10.1097/00045413-199409000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Myers, Renelle. "Asbestos-related pleural disease." Current Opinion in Pulmonary Medicine 18, no. 4 (July 2012): 377–81. http://dx.doi.org/10.1097/mcp.0b013e328354acfe.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Weber, Marc-André, Michael Bock, Christian Plathow, Klaus Wasser, Christian Fink, Ivan Zuna, Astrid Schmähl, Irina Berger, Hans-Ulrich Kauczor, and Stefan O. Schoenberg. "Asbestos-Related Pleural Disease." Investigative Radiology 39, no. 9 (September 2004): 554–64. http://dx.doi.org/10.1097/01.rli.0000131888.39636.c5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Solbes, Eduardo, and Richart W. Harper. "Biological responses to asbestos inhalation and pathogenesis of asbestos-related benign and malignant disease." Journal of Investigative Medicine 66, no. 4 (January 6, 2018): 721–27. http://dx.doi.org/10.1136/jim-2017-000628.

Full text

Abstract:

Asbestos comprises a group of fibrous minerals that are naturally occurring in the environment. Because of its natural properties, asbestos gained popularity for commercial applications in the late 19th century and was used throughout the majority of the 20th century, with predominant use in the construction, automotive, and shipbuilding industries. Asbestos has been linked to a spectrum of pulmonary diseases, such as pleural fibrosis and plaques, asbestosis, benign asbestos pleural effusion, small cell lung carcinoma, non-small cell lung carcinoma, and malignant mesothelioma. There are several mechanisms through which asbestos can lead to both benign and malignant disease, and they include alterations at the chromosomal level, activation of oncogenes, loss of tumor suppressor genes, alterations in cellular signal transduction pathways, generation of reactive oxygen and nitrogen species, and direct mechanical damage to cells from asbestos fibers. While known risk factors exist for the development of asbestos-related malignancies, there are currently no effective means to determine which asbestos-exposed patients will develop malignancy and which will not. There are also no established screening strategies to detect asbestos-related malignancies in patients who have a history of asbestos exposure. In this article, we present a case that highlights the different biological responses in human hosts to asbestos exposure.

APA, Harvard, Vancouver, ISO, and other styles

10

Beritić, Tihomil, and Silvija Kovač. "Asbestos-related disease without asbestosis — why not pleural asbestosis?" American Journal of Industrial Medicine 8, no. 6 (1985): 517–20. http://dx.doi.org/10.1002/ajim.4700080603.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Lococo, Filippo. "Malignant Pleural Mesothelioma: Time Is Running Out." Journal of Clinical Medicine 10, no. 4 (February 8, 2021): 648. http://dx.doi.org/10.3390/jcm10040648.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Rosenstock, Linda, and Leonard Hudson. "Nonmalignant Asbestos-Induced Pleural Disease." Seminars in Respiratory and Critical Care Medicine 7, no. 03 (January 1986): 197–202. http://dx.doi.org/10.1055/s-2007-1012615.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

PEACOCK, C., S. J. COPLEY, and D. M. HANSELL. "Asbestos-Related Benign Pleural Disease." Clinical Radiology 55, no. 6 (June 2000): 422–32. http://dx.doi.org/10.1053/crad.2000.0450.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

MORCOS, S. K. "ASBESTOS-RELATED BENIGN PLEURAL DISEASE." Clinical Radiology 56, no. 1 (January 2001): 85. http://dx.doi.org/10.1053/crad.2000.0581.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

King, Christopher, Danira Mayes, and David A. Dorsey. "Benign Asbestos-Related Pleural Disease." Disease-a-Month 57, no. 1 (January 2011): 27–39. http://dx.doi.org/10.1016/j.disamonth.2010.12.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Dallmann, Adam, and Richard L. Attanoos. "Yellow Nail Syndrome with Bilateral Pleural Plaques and Diffuse Pleural Thickening: A Mimic of Asbestos Related Disease." Case Reports in Pulmonology 2018 (September 24, 2018): 1–3. http://dx.doi.org/10.1155/2018/7302898.

Full text

Abstract:

Yellow nail syndrome is a rare acquired condition of unknown aetiology associated with distinct nail discolouration/xanthonychia, pulmonary manifestations, and lymphoedema. Pleural plaques and diffuse pleural thickening are typically, although not exclusively, recognised as markers of prior commercial asbestos exposure. The presence of such biomarkers may assist an asbestos personal injury evaluation. A postmortem examination performed on a 72-year-old man with known long-standing yellow nail syndrome identified pleural plaques and diffuse pleural thickening. An evaluation of the occupational history identified no known asbestos exposure. Electron microscopic mineral fibre analysis detected no asbestos fibres. To the best of our knowledge, this is the only case of yellow nail syndrome in which these benign pleural changes are reported ex asbestos. Alternate causes for such pleural pathology were absent. There is merit in physicians and pathologists having an awareness of these new manifestations when considering claimed asbestos related changes during life and at postmortem.

APA, Harvard, Vancouver, ISO, and other styles

17

Pais, Ana, Nicole Pinto, João Cardoso, Manuel Fernandes, Ana Isabel Coutinho, Ana Sofia Oliveira, Lurdes Carvalho, and Cristina Bárbara. "Mesotelioma Intraparenquimatoso Difuso: Uma Apresentação Rara." Acta Médica Portuguesa 33, no. 2 (February 3, 2020): 143. http://dx.doi.org/10.20344/amp.11406.

Full text

Abstract:

Pleural mesothelioma is a disease associated with exposure to asbestos. Although rare, it is the most common malignant pleural neoplasm. It is difficult to diagnose and it has a poor prognosis. We report the case of a 62-year-old male patient with a history of prolonged occupational exposure to asbestos, with dyspnea for minor exertion and productive cough, for several months. Imaging studies revealed extensive interstitial involvement with marked thickening of the interlobular and centrilobular septa and tenuous pleural involvement. Several differential diagnoses were considered such as, asbestosis, cryptogenic organizing pneumonia, desquamative interstitial pneumonia, pleuropulmonary metastases, and/or bronchopulmonary infection, but the histological and immunohistochemical results were compatible with pleural mesothelioma - a rare malignant neoplasm, with pleural origin, with a high mortality rate.

APA, Harvard, Vancouver, ISO, and other styles

18

Fujimoto, Nobukazu, Kenichi Gemba, Keisuke Aoe, Katsuya Kato, Takako Yokoyama, Ikuji Usami, Kazuo Onishi, Keiichi Mizuhashi, Toshikazu Yusa, and Takumi Kishimoto. "Clinical Investigation of Benign Asbestos Pleural Effusion." Pulmonary Medicine 2015 (2015): 1–6. http://dx.doi.org/10.1155/2015/416179.

Full text

Abstract:

There is no detailed information about benign asbestos pleural effusion (BAPE). The aim of the study was to clarify the clinical features of BAPE. The criteria of enrolled patients were as follows: (1) history of asbestos exposure; (2) presence of pleural effusion determined by chest X-ray, CT, and thoracentesis; and (3) the absence of other causes of effusion. Clinical information was retrospectively analysed and the radiological images were reviewed. There were 110 BAPE patients between 1991 and 2012. All were males and the median age at diagnosis was 74 years. The median duration of asbestos exposure and period of latency for disease onset of BAPE were 31 and 48 years, respectively. Mean values of hyaluronic acid, adenosine deaminase, and carcinoembryonic antigen in the pleural fluid were 39,840 ng/mL, 23.9 IU/L, and 1.8 ng/mL, respectively. Pleural plaques were detected in 98 cases (89.1%). Asbestosis was present in 6 (5.5%) cases, rounded atelectasis was detected in 41 (37.3%) cases, and diffuse pleural thickening (DPT) was detected in 30 (27.3%) cases. One case developed lung cancer (LC) before and after BAPE. None of the cases developed malignant pleural mesothelioma (MPM) during the follow-up.

APA, Harvard, Vancouver, ISO, and other styles

19

Miller, A. "Pulmonary Function in Asbestosis and Asbestos-Related Pleural Disease." Environmental Research 61, no. 1 (April 1993): 1–18. http://dx.doi.org/10.1006/enrs.1993.1044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Dipalma, Nicola, Vito Luisi, Francesca Di Serio, Antonietta Fontana, Piera Maggiolini, Brunella Licchelli, Ernesto Mera, et al. "Biomarkers in Malignant Mesothelioma: Diagnostic and Prognostic Role of Soluble Mesothelin-Related Peptide." International Journal of Biological Markers 26, no. 3 (July 2011): 160–65. http://dx.doi.org/10.5301/jbm.2011.8614.

Full text

Abstract:

Soluble mesothelin-related peptide (SMRP) is a biomarker that has been proposed for differential diagnosis from pleural metastatic cancer, as well as prognosis and treatment monitoring of malignant pleural mesothelioma (MM). The aim of this study was to evaluate the role of SMRP in clinic management of MM. We assayed the SMRP concentrations in 354 subjects: 109 healthy volunteers with no history of exposure to asbestos, 26 patients with previous occupational asbestos exposure but who were free from pleural or parenchymal disease, 48 patients with asbestosis, 110 patients with pleural plaques, 25 patients with lung cancer, and 36 patients with MM. We also tested SMRP titers in 2 patients with MM at 5 different times of the disease, to evaluate the trend of the biomarker in the course of therapy. Our data confirm previous experiences with the use of SMRP as a diagnostic marker of MM. Low SMRP levels at diagnosis seem to have a positive prognostic significance.

APA, Harvard, Vancouver, ISO, and other styles

21

Ak, Guntulu, Sandra C. Tomaszek, Farhad Kosari, Muzaffer Metintas, James R. Jett, Selma Metintas, Huseyin Yildirim, et al. "MicroRNA and mRNA Features of Malignant Pleural Mesothelioma and Benign Asbestos-Related Pleural Effusion." BioMed Research International 2015 (2015): 1–8. http://dx.doi.org/10.1155/2015/635748.

Full text

Abstract:

Introduction. We investigated the expression of microRNAs and mRNAs in pleural tissues from patients with either malignant pleural mesothelioma or benign asbestos-related pleural effusion.Methods. Fresh frozen tissues from a total of 18 malignant pleural mesothelioma and 6 benign asbestos-related pleural effusion patients were studied. Expression profiling of mRNA and microRNA was performed using standard protocols.Results. We discovered significant upregulation of multiple microRNAs in malignant pleural mesothelioma compared to benign asbestos-related pleural effusion. Hsa-miR-484, hsa-miR-320, hsa-let-7a, and hsa-miR-125a-5p were able to discriminate malignant from benign disease. Dynamically regulated mRNAs were also identified. MET was the most highly overexpressed gene in malignant pleural mesothelioma compared to benign asbestos-related pleural effusion. Integrated analyses examining microRNA-mRNA interactions suggested multiple altered targets within the Notch signaling pathway.Conclusions. Specific microRNAs and mRNAs may have diagnostic utility in differentiating patients with malignant pleural mesothelioma from benign asbestos-related pleural effusion. These studies may be particularly helpful in patients who reside in a region with a high incidence of mesothelioma.

APA, Harvard, Vancouver, ISO, and other styles

22

Manfredo, Irena. "Accidental discovery of asbestos-related occupational pleural disease in unemployed carpenter: a healthcare safety net that needs mending / Poklicna bolezen plevre zaradi izpostavljenosti azbestu pri mizarju." Archives of Industrial Hygiene and Toxicology 66, no. 3 (September 1, 2015): 213–15. http://dx.doi.org/10.1515/aiht-2015-66-2682.

Full text

Abstract:

Abstract Unemployed persons are often on the margins of the healthcare system and under the radar of safety and health organisations, as no systematic records are kept of occupational diseases caused by exposure at previous work place. Law in Slovenia requires that asbestos-related occupational diseases are verified by establishing the causal relationship between exposure at work and its effect on the worker. This report describes a case of verifying occupational pleural disease in an unemployed carpenter who was referred for consultation with occupational health specialist as part of the regular procedure for the unemployed registered at the Employment Service of Slovenia. At the consultation it turned out that the carpenter had been exposed to asbestos when he worked as a teenage apprentice. The diagnosis of the bilateral pleural disease and asbestosis was confirmed by X-ray and high-resolution computed tomography. Because he had no record of exposure in that period, we analysed his past working environment for minerals and found chrysotile in all asbestos board samples. The case was presented to an interdisciplinary committee, which verified his disease as occupational. This case points to the need of adopting guidelines for occupational health specialists providing counsel to the national employment service so that the number of unrecorded occupational diseases is minimised and their treatment is covered by the state.

APA, Harvard, Vancouver, ISO, and other styles

23

Zantah, Massa, and Debapriya Datta. "Tuberculous pleural effusion occurring concurrently with asbestos-related pleural disease." Respiratory Medicine Case Reports 21 (2017): 135–37. http://dx.doi.org/10.1016/j.rmcr.2017.04.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Rudd, R. M. "New developments in asbestos-related pleural disease." Thorax 51, no. 2 (February 1, 1996): 210–16. http://dx.doi.org/10.1136/thx.51.2.210.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Sison, Rebecca F., Ralph H. Hruban, G. William Moore, Janet E. Kuhlman, Paul S. Wheeler, and Grover M. Hutchins. "Pulmonary Disease Associated with Pleural “Asbestos” Plaques." Chest 95, no. 4 (April 1989): 831–35. http://dx.doi.org/10.1378/chest.95.4.831.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Schwartz, David A. "New Developments in Asbestos-Induced Pleural Disease." Chest 99, no. 1 (January 1991): 191–98. http://dx.doi.org/10.1378/chest.99.1.191.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Hillerdal, Gunnar. "Nonmalignant Pleural Disease Related to Asbestos Exposure." Clinics in Chest Medicine 6, no. 1 (March 1985): 141–52. http://dx.doi.org/10.1016/s0272-5231(21)00345-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Mustard, F., and Robert G. Fraser. "Diagnosis of Asbestosis and Asbestos-Related Pleural Disease by Imaging Methods." Chest 89, no. 4 (April 1986): 366S—367S. http://dx.doi.org/10.1378/chest.89.4_supplement.366s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Vehmas, Tapio, Asta Hiltunen, Leena Kivisaari, and Päivi Leino-Arjas. "Atherosclerotic and pleural calcifications are related among asbestos-exposed workers." European Journal of Cardiovascular Prevention & Rehabilitation 15, no. 5 (October 2008): 599–601. http://dx.doi.org/10.1097/hjr.0b013e328309a224.

Full text

Abstract:

Methods We studied the relationship between calcified chest atherosclerosis and pleural plaques among 505 construction workers with computed tomography. The extent and thickness of pleural plaques and the score of visceral pleural thickening were estimated, as was calcification of both pleural disease and chest atherosclerosis. Results Adjusted for age, BMI, smoking, and asbestos exposure, pleural calcification was associated with calcification in coronary arteries ( P < 0.001) and in the aorta ( P < 0.001). Conclusion These associations may be due to susceptibility factors common to both conditions. Calcification in pleural plaques may be a hint of atherosclerosis at least among asbestos-exposed people.

APA, Harvard, Vancouver, ISO, and other styles

30

Onishi, Yasutaka, Yasuharu Nakahara, Katsuya Hirano, Shin Sasaki, Tetsuji Kawamura, and Yoshiro Mochiduki. "IgG 4‐related disease in asbestos‐related pleural disease." Respirology Case Reports 4, no. 1 (December 30, 2015): 22–24. http://dx.doi.org/10.1002/rcr2.142.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Česas, Alvydas, Algirdas Šlepavičius, Aleksandras Bagajevas, and Rugilė Česaitė. "Multidisciplinary Treatment Of Malignant Pleural And Peritoneal Mesothelioma In Klaipeda University Hospital. Case Report." Sveikatos mokslai 26, no. 5 (December 22, 2016): 40–47. http://dx.doi.org/10.5200/sm-hs.2016.070.

Full text

Abstract:

Malignant mesothelioma is an aggressive tumor of serosal surfaces, such as the pleura, the peritoneum, the pericardium and the tunica vaginalis. There is a substantial interest in this disease by part of medical community and the general public because millions of people have been exposed to asbestos fibers, and many articles about the dangers of asbestos had appeared in the press. 80 percent of patients with pleural malignant mesothelioma are male, commonly present with a pleural effusion, associated with breathlessness and often accompanied by chest-wall pain (more than 60 percent of patients). The main cause of malignant mesothelioma is exposure to asbestos – the carcinogen associated with malignant mesothelioma. Indeed, malignant mesothelioma was rare before the widespread use of asbestos, and increasing incidence worldwide is expected to peak in 5 to 10 years. The pathologic diagnostic of malignant mesothelioma is very difficult even with pathology experts in mesothelioma. Accurate and rapid diagnosis of malignant mesothelioma is important for therapeutic reasons. The most frequent diagnostic problem is the differentiation of malignant mesothelioma and adenocarcinoma – a distinction that is particularly difficult to make when the tumor has invaded the pleura. For many years surgery has proved to be most useful for palliation – for example, for local control of recurrent effusions. Debulking surgery is used in some centers until now. Systemic chemotherapy, cytoreductive surgery, HYPEC and multidisciplinary team discussion can help to cure or extend survival of patients. The case report showed successful multidisciplinary approach treatment for young man with malignant pleural and peritoneal mesothelioma.

APA, Harvard, Vancouver, ISO, and other styles

32

Lopes, Luiz Antonio Coelho, and Mara Telles Salles. "Asbestos and Alternative Materials." Applied Mechanics and Materials 548-549 (April 2014): 61–66. http://dx.doi.org/10.4028/www.scientific.net/amm.548-549.61.

Full text

Abstract:

Asbestos is the trade name of material widely used in construction, especially in BRICS members. The high usage of asbestos due to its low cost coupled with their properties, such as electrical resistance, tensile strength, heat resistance and some acids, in addition to its flexibility derived from its fibrous feature, which allows it to be woven. However, it is also known that asbestos in the process of extraction and production is extremely dangerous for workers. Very thin fibers tend to turn into powder that is deposited in the lungs of workers, which may lead to loss of breathing capacity, pleural plaques, some cancers, and most often a disease called asbestosis. Although there is a tendency to ban asbestos in all regions and countries, as already occurs in the European Union, Brazil, and other countries with large housing deficit, maintains the use of asbestos in the production of fiber cement tiles. The article aims to discuss the dilemma of controlled use and ban asbestos, and present the progress of the search for alternative materials to asbestos in Brazil.

APA, Harvard, Vancouver, ISO, and other styles

33

van der Heijden, H. F. M., Y. F. Heijdra, J. Bulten, and J. Festen. "Pleural small cell carcinoma in pre-existent asbestos related pleural disease." Lung Cancer 35, no. 1 (January 2002): 91–94. http://dx.doi.org/10.1016/s0169-5002(01)00326-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

DESHPANDE, A., and N. J. SCREATON. "Mesothelioma- and asbestos-related pleural disease: a review." Imaging 22, no. 1 (May 2013): 20120027. http://dx.doi.org/10.1259/imaging.20120027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Kilburn, Kaye H., and Raphael Warshaw. "Pulmonary Functional Impairment Associated with Pleural Asbestos Disease." Chest 98, no. 4 (October 1990): 965–72. http://dx.doi.org/10.1378/chest.98.4.965.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

ROSENSTOCK, LINDA, and LEONARD D. HUDSON. "The Increasing Importance of Asbestos-Related Pleural Disease." Annals of the New York Academy of Sciences 643, no. 1 The Third Wav (December 1991): 296–300. http://dx.doi.org/10.1111/j.1749-6632.1991.tb24475.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Sprince, N. L., L. C. Oliver, T. C. Mcloud, E. A. Eisen, D. C. Christiani, and L. C. Ginns. "Asbestos Exposure and Asbestos-related Pleural andParenchymal Disease: Associations with Immune Imbalance." American Review of Respiratory Disease 143, no. 4_pt_1 (April 1991): 822–28. http://dx.doi.org/10.1164/ajrccm/143.4_pt_1.822.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Mozzoni, Paola, Luca Ampollini, Matteo Goldoni, Rossella Alinovi, Marcello Tiseo, Letizia Gnetti, Paolo Carbognani, et al. "MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study." Disease Markers 2017 (2017): 1–10. http://dx.doi.org/10.1155/2017/9645940.

Full text

Abstract:

Background. The identification of diagnostic/prognostic biomarkers for asbestos-related diseases is relevant for early diagnosis and patient survival and may contribute to understanding the molecular mechanisms underlying the disease development and progression.Aims. To identify a pattern of miRNAs as possible diagnostic biomarkers for patients with malignant pleural mesothelioma (MPM) and asbestosis (ASB) and as prognostic biomarkers for MPM patients.Methods. miRNA-16, miRNA-17, miRNA-126, and miRNA-486 were quantified in plasma and formalin-fixed paraffin-embedded samples to evaluate their diagnostic and prognostic roles compared to patients with other noncancerous pulmonary diseases (controls). Results. The expression of all the miRNAs was significantly lower in patients with MPM and ASB than that in controls. miRNA-16, miRNA-17, and miRNA-486 in plasma and tissue of MPM patients were significantly correlated. Furthermore, the expression of miRNA-16 in plasma and tissue, and miRNA-486 only in tissue, was positively related with cumulative survival in MPM patients.Conclusions. All the miRNA levels were decreased in patients with MPM or ASB, supporting the role of circulating miRNAs as a potential tool for diseases associated with exposure to asbestos fibers. miRNA-16 was directly related to MPM patient prognosis, suggesting its possible use as a prognostic marker in MPM patients.

APA, Harvard, Vancouver, ISO, and other styles

39

Majurin, M. L., M. Varpula, T. Kurki, and L. Pakkala. "High-Resolution CT of the Lung in Asbestos-Exposed Subjects." Acta Radiologica 35, no. 5 (September 1994): 473–77. http://dx.doi.org/10.1177/028418519403500516.

Full text

Abstract:

The lowest possible mAs settings for high-resolution CT (HRCT) were studied on 45 individuals with suspected asbestos-related lung disease. All patients were investigated with 5 to 6 high-dose HRCT images (120 kVp/160 mA/2 s) at 3-cm intervals. At a selected level 4 additional low-dose images were obtained on each patient with lower mAs settings (100 mA/2 s, 80 mA/2 s, 60 mA/2 s, 30 mA/2 s). Thirty-seven subjects out of 45 had HRCT lesions compatible with asbestosis. HRCT images obtained with as low as 60 mA/2 s settings clearly showed pleural tractions and thickenings, parenchymal bands, honeycombing and subpleural curvilinear shadows, whereas in the evaluation of subpleural short lines and ground glass findings 80 mA/2 s were required. The lowest setting, 30 mA/2 s, was sufficient only in detecting and evaluating pleural tractions and thickenings. We conclude that 160 mAs yield good quality HRCT images, with substantial decrease of radiation dose, for the evaluation of asbestos-related lesions.

APA, Harvard, Vancouver, ISO, and other styles

40

Friedman, AC, SB Fiel, MS Fisher, PD Radecki, AS Lev-Toaff, and DF Caroline. "Asbestos-related pleural disease and asbestosis: a comparison of CT and chest radiography." American Journal of Roentgenology 150, no. 2 (February 1988): 269–75. http://dx.doi.org/10.2214/ajr.150.2.269.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Creaney, Jenette, Sophie Sneddon, Ian M. Dick, Hanne Dare, Neil Boudville, Arthur William Musk, Steven J. Skates, and Bruce W. S. Robinson. "Comparison of the Diagnostic Accuracy of theMSLNGene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum." Disease Markers 35 (2013): 119–27. http://dx.doi.org/10.1155/2013/874212.

Full text

Abstract:

TheMSLNgene products, soluble mesothelin and megakaryocyte potentiating factor (MPF), are being investigated as biomarkers for the asbestos-related cancer malignant mesothelioma (MM). Pleural fluid biomarkers of MM can be elevated when serum levels remain normal. The aim of this study was to determine if this was true for MPF and to compare levels of mesothelin. Biomarker concentrations were compared in 66 MM patients, 39 patients with other malignancies, 37 with benign disease, 18 asbestos-exposed healthy individuals, and 53 patients with chronic kidney disease. In pleural effusions, MPF and soluble mesothelin concentrations were both significantly elevated in MM patients relative to controls. No significant difference between the area under the receiver operator curve (AUC) for MPF (0.945±0.02) and mesothelin (0.928±0.03) when distinguishing MM from all other causes of effusion was observed. MPF and mesothelin serum concentrations were highly correlated and of equivalent diagnostic accuracy with AUCs of0.813±0.04and0.829±0.03, respectively. Serum levels of both markers increased with decreasing kidney function. In conclusion, MPF is elevated in the pleural effusions of MM patients similar to that of mesothelin. Mesothelin and MPF convey equivalent diagnostic information for distinguishing MM from other diseases in pleural effusions as well as serum.

APA, Harvard, Vancouver, ISO, and other styles

42

Lee, Y. C. Gary, Nicholas H. De Klerk, and A. William Musk. "Asbestos‐related pleural disease in Western Australian gold‐miners." Medical Journal of Australia 170, no. 6 (March 1999): 263–65. http://dx.doi.org/10.5694/j.1326-5377.1999.tb127749.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Hu, Howard, Laurel Beckett, Karl Kelsey, and David Christiani. "The Left-sided Predominance of Asbestos-related Pleural Disease." American Review of Respiratory Disease 148, no. 4_pt_1 (October 1993): 981–84. http://dx.doi.org/10.1164/ajrccm/148.4_pt_1.981.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Kouris, S. P., D. L. Parker, A. P. Bender, and A. N. Williams. "Effects of asbestos-related pleural disease on pulmonary function." Scandinavian Journal of Work, Environment & Health 17, no. 3 (June 1991): 179–83. http://dx.doi.org/10.5271/sjweh.1713.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Hunter, Wesley, Veronica Arteaga, and Diana Palacio. "Medical image of the week: asbestos related pleural disease." Southwest Journal of Pulmonary and Critical Care 15, no. 3 (September 13, 2017): 116–17. http://dx.doi.org/10.13175/swjpcc104-17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Carder, Melanie, Andrew Darnton, Matthew Gittins, S. Jill Stocks, David Ross, Chris M. Barber, and Raymond M. Agius. "Chest physician-reported, work-related, long-latency respiratory disease in Great Britain." European Respiratory Journal 50, no. 6 (December 2017): 1700961. http://dx.doi.org/10.1183/13993003.00961-2017.

Full text

Abstract:

Much of the current burden of long-latency respiratory disease (LLRD) in Great Britain is attributed to historical asbestos exposure. However, continuing exposure to other agents, notably silica, also contributes to disease burden. The aim of this study was to investigate the incidence of work-related LLRD reported by chest physicians in Great Britain, including variations by age, gender, occupation and suspected agent.LLRD incidence and incidence rate ratios by occupation were estimated (1996–2014). Mesothelioma cases by occupation were compared with proportional mortality ratios.Cases were predominantly in men (95%) and 92% of all cases were attributed to asbestos. Annual average incidence rates (males) per 100 000 were: benign pleural disease, 7.1 (95% CI 6.0–8.2); mesothelioma, 5.4 (4.8–6.0); pneumoconiosis, 1.9 (1.7–2.2); lung cancer, 0.8 (0.6–1.0); chronic obstructive pulmonary disease (COPD), 0.3 (0.2–0.4). Occupations with a particularly high incidence of LLRD were miners and quarrymen (COPD), plumbers and gas fitters (asbestosis), and shipyard and dock workers (all other categories). There was a clear concordance between cases of SWORD mesothelioma and proportional mortality ratios by occupation.Occupationally caused LLRD continues to contribute to a significant disease burden. Many cases are attributable to past exposure to agents such as asbestos and silica, but the potential for occupational exposures persists.

APA, Harvard, Vancouver, ISO, and other styles

47

Butnian, Krittachat, Nisa Muangman, Kanyarat Totanarungroj, and Suwimon Wonglaksanapimon. "Differentiation Between the Aalignant Mesothelioma of Pleura and Pleural Metastasis with Contrast Enhanced CT, Is It Possible?" Siriraj Medical Journal 73, no. 9 (September 1, 2021): 594–602. http://dx.doi.org/10.33192/smj.2021.77.

Full text

Abstract:

Objective: To compare CT findings between malignant pleural mesothelioma (MPM) and metastatic pleuraldisease (MPD).Materials and Methods: CT chest images of 157 cases of pathologically-proven malignant pleural disease(21 MPM, 136 MPD) were retrospectively reviewed by two radiologists who were blinded to the diagnosis. Findingsof interest included pleural effusion, pleural thickening, organ invasion, lymphadenopathy, dominant lung nodule,pulmonary or extra-thoracic organ metastasis, and asbestos-related disease.Results: Findings commonly found in MPM compared with MPD are circumferential pleural thickening (52.4%vs 14.0%, p<0.001), pleural mass (33.3% vs 7.4%, p<0.001), organs invasion (57.1% vs 9.6%, p<0.001), and asbestosrelated disease (19% vs 0%, p<0.001).Conclusions: Circumferential pleural thickening, pleural mass, presence of organ invasion, and CT finding ofasbestos-related pleural disease were the CT findings that raise the possibility of MPM.

APA, Harvard, Vancouver, ISO, and other styles

48

Brims, Fraser. "Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma." Cancers 13, no. 16 (August 20, 2021): 4194. http://dx.doi.org/10.3390/cancers13164194.

Full text

Abstract:

Mesothelioma is a cancer predominantly of the pleural cavity. There is a clear association of exposure to asbestos with a dose dependent risk of mesothelioma. The incidence of mesothelioma in different countries reflect the historical patterns of commercial asbestos utilisation in the last century and predominant occupational exposures mean that mesothelioma is mostly seen in males. Modern imaging techniques and advances in immunohistochemical staining have contributed to an improved diagnosis of mesothelioma. There have also been recent advances in immune checkpoint inhibition, however, mesothelioma remains very challenging to manage, especially considering its limited response to conventional systemic anticancer therapy and that no cure exists. Palliative interventions and support remain paramount with a median survival of 9–12 months after diagnosis. The epidemiology and diagnosis of mesothelioma has been debated over previous decades, due to a number of factors, such as the long latent period following asbestos exposure and disease occurrence, the different potencies of the various forms of asbestos used commercially, the occurrence of mesothelioma in the peritoneal cavity and its heterogeneous pathological and cytological appearances. This review will describe the contemporary knowledge on the epidemiology of mesothelioma and provide an overview of the best clinical practice including diagnostic approaches and management.

APA, Harvard, Vancouver, ISO, and other styles

49

Brims, F. J. H. "Asbestos – a legacy and a persistent problem." Journal of The Royal Naval Medical Service 95, no. 1 (March 2009): 4–11. http://dx.doi.org/10.1136/jrnms-95-4.

Full text

Abstract:

AbstractAsbestos has been utilised by industrialised nations for over a century and its deleterious health effects have been reported for an almost equal length of time. Whilst developed countries have now reduced their asbestos use, developing nations are increasing their asbestos imports and consumption. Because of this, there is now a perceived risk to Non Government Organisation and military personnel involved in aid operations or conflict areas, where asbestos containing materials and buildings may have been disrupted.With significant asbestos exposures to UK military and dockyard personnel in the past, the health consequences are continuing to increase, with the incidence of malignant mesothelioma expected to continue to rise until between 2012-2020. There is no effective cure or treatment for any of the lung or pleural asbestos related diseases; malignant mesothelioma has a median survival of just 6-12 months. Misconceptions about asbestos are widespread, contributed in part by a long latency between exposure and disease. Following diagnosis of an asbestos related disease, financial recompense for exservice personnel is limited, and the civilian legal implications continue to change. This review will encompass the historical usage of asbestos, its biological effects, the legal and financial implications of exposure, and establish that there may be a continuing threat of exposure to deployed military personnel

APA, Harvard, Vancouver, ISO, and other styles

50

Abbott, David Michael, Chandra Bortolotto, Silvia Benvenuti, Andrea Lancia, Andrea Riccardo Filippi, and Giulia Maria Stella. "Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge." Cancers 12, no. 5 (May 7, 2020): 1186. http://dx.doi.org/10.3390/cancers12051186.

Full text

Abstract:

Mesothelioma is a malignancy of serosal membranes including the peritoneum, pleura, pericardium and the tunica vaginalis of the testes. Malignant mesothelioma (MM) is a rare disease with a global incidence in countries like Italy of about 1.15 per 100,000 inhabitants. Malignant Pleural Mesothelioma (MPM) is the most common form of mesothelioma, accounting for approximately 80% of disease. Although rare in the global population, mesothelioma is linked to industrial pollutants and mineral fiber exposure, with approximately 80% of cases linked to asbestos. Due to the persistent asbestos exposure in many countries, a worldwide progressive increase in MPM incidence is expected for the current and coming years. The tumor grows in a loco-regional pattern, spreading from the parietal to the visceral pleura and invading the surrounding structures that induce the clinical picture of pleural effusion, pain and dyspnea. Distant spreading and metastasis are rarely observed, and most patients die from the burden of the primary tumor. Currently, there are no effective treatments for MPM, and the prognosis is invariably poor. Some studies average the prognosis to be roughly one-year after diagnosis. The uniquely poor mutational landscape which characterizes MPM appears to derive from a selective pressure operated by the environment; thus, inflammation and immune response emerge as key players in driving MPM progression and represent promising therapeutic targets. Here we recapitulate current knowledge on MPM with focus on the emerging network between genetic asset and inflammatory microenvironment which characterize the disease as amenable target for novel therapeutic approaches.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!